Loading clinical trials...
Loading clinical trials...
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Assess Aesthetic Improvement and Onset of QM1114-DP Treatment Effect in Subjects With Moderate to Severe Glabellar Lines
Conditions
Interventions
QM1114-DP
Placebo
Locations
9
United States
Galderma Research Site
Homewood, Alabama, United States
Galderma Research Site
Manhattan Beach, California, United States
Galderma Research Site
Vista, California, United States
Galderma Research Site
Coral Gables, Florida, United States
Galderma Research Site
Hunt Valley, Maryland, United States
Galderma Research Site
Omaha, Nebraska, United States
Start Date
May 9, 2022
Primary Completion Date
October 28, 2022
Completion Date
September 1, 2023
Last Updated
October 21, 2024
NCT05481931
NCT06411002
NCT05148000
NCT05277337
NCT04249583
NCT05217355
Lead Sponsor
Galderma R&D
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions